PIQRAY (alpelisib) – To treat breast cancer
PIQRAY DOSAGE AND ADMINISTRATION
- Recommended dose: 300 mg (two 150 mg tablets) taken orally once daily with food.
- For adverse reactions, consider dose interruption, dose reduction, or discontinuation.
PIQRAY INDICATIONS AND USAGE
PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
PIQRAY ADVERSE REACTIONS
Most common adverse reactions including laboratory abnormalities (all grades, incidence ≥ 20%) were glucose increased, creatinine increased,
diarrhea, rash, lymphocyte count decreased, GGT increased, nausea, ALT increased, fatigue, hemoglobin decreased, lipase increased, decreased appetite, stomatitis, vomiting, weight decreased, calcium decreased, glucose decreased, aPTT prolonged, and alopecia.
PIQRAY DRUG INTERACTIONS
- CYP3A4 Inducers: Avoid coadministration of PIQRAY with a strong CYP3A4 inducer.
- BCRP Inhibitors: Avoid the use of BCRP inhibitors in patients treated with PIQRAY. If unable to use alternative drugs, closely monitor for increased adverse reactions.
- CYP2C9 Substrates: Closely monitor when PIQRAY is coadministered with CYP2C9 substrates where decreases in the plasma concentration of
these drugs may reduce activity.
PIQRAY DOSAGE FORMS AND STRENGTHS
Tablets: 50 mg, 150 mg, 200 mg
PIQRAY USE IN SPECIFIC POPULATIONS
Lactation: Advise not to breastfeed